Oncoinvent ASA – Mandatory notification of trade – Allocation and share lending in Private Placement
Oslo, 23 September 2026: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the "Company") on 22 September 2026 regarding completion of a private placement of 1,650,000 new shares at a subscription price of NOK 90 per share (the "Subscription Price") (the "Private Placement").
Prior to the share lending described below, Hadean Capital I AS, HVentures Capital I AB and Hadean Growth Fund I AS held an aggregate of 554,327 shares in the Company, equal to approximately 12.38% of the shares and votes in the Company.
Hadean Capital I AS held, prior to the Private placement 312.280 shares in the Company, equal to 6.97% of the shares and votes in the Company.
Hadean Capital I AS has subscribed for and been allocated 108,469 new shares in the Private Placement at the Subscription Price. In addition, and solely to facilitate delivery-versus-payment ("DVP") settlement of shares allocated to investors in the Private Placement, Hadean Capital I AS has, pursuant to a share lending agreement, agreed to temporarily lend 312,280 existing and unencumbered shares in the Company to ABG Sundal Collier ASA and DNB Carnegie, a part of DNB Bank ASA, acting as managers in the Private Placement (the "Managers"). As a result of the share lending, Hadean Capital I AS will temporarily reduce its shareholding to 0 shares in the Company thereby crossing below the 5% reporting threshold pursuant to the Norwegian Securities Trading Act (the "NSTA"). Following receipt of the new shares allocated in the Private Placement, Hadean Capital I AS will increase its holding to 108,469 shares, equal to 1.77% of the total number of shares and votes in the Company calculated on the basis of the new share capital following completion of the Private Placement. Upon re-delivery of the lent shares, Hadean Capital I AS will further increase its holding to 420,749 shares and votes, equal to 6.87%% of the total number of shares and votes in the company calculated on the basis of the new share capital following completion of the Private Placement, thereby crossing above the 5% reporting threshold pursuant to the NSTA.
HVentures Capital I AB held, prior to the Private placement 141,642 shares in the Company, equal to 3.16% of the shares and votes in the Company.
HVentures Capital I AB has subscribed for and been allocated 49,199 new shares in the Private Placement at the Subscription Price and has, for the same purpose, agreed to temporarily lend 141,642 existing and unencumbered shares in the Company to the Managers. As a result of the share lending, HVentures Capital I AB will temporarily reduce its shareholding to 0 shares in the Company. Following receipt of the new shares allocated in the Private Placement, HVentures Capital I AB will increase its holding to 49,199 shares, equal to 0.80% of the total number of shares and votes in the Company calculated on the basis of the new share capital following completion of the Private Placement. Upon re-delivery of the lent shares, HVentures Capital I AB will further increase its holding to 190,841 shares, equal to 3.11% of the total number of shares and votes in the company calculated on the basis of the new share capital following completion of the Private Placement.
Hadean Growth Fund I AS held, prior to the Private placement 100,405 shares in the Company, equal to 2.24% of the shares and votes in the Company.
Hadean Growth Fund I AS has subscribed for and been allocated 34,875 new shares in the Private Placement at the Subscription Price and has, for the same purpose, agreed to temporarily lend 100,405 existing and unencumbered shares in the Company to the Managers. As a result of the share lending, Hadean Growth Fund I AS will temporarily reduce its shareholding to 0 shares in the Company. Following receipt of the new shares allocated in the Private Placement, Hadean Growth Fund I AS will increase its holding to 34,875 shares, equal to 0.57% of the total number of shares and votes in the Company calculated on the basis of the new share capital following completion of the Private Placement. Upon re-delivery of the lent shares, Hadean Growth Fund I AS will further increase its holding to 135,280 shares, equal to 2.21% of the total number of shares and votes in the company calculated on the basis of the new share capital following completion of the Private Placement.
As a result of the temporary share lending, the reportable aggregate shareholding of Hadean Capital I AS, HVentures Capital I AB and Hadean Growth Fund I AS will temporarily be reduced from 554,327 shares to 0 shares, thereby passing down below the 10% and 5% substantial shareholding disclosure thresholds pursuant to the NSTA on a consolidated basis. Following receipt of the new shares allocated in the Private Placement, the consolidated shareholding will be increased to 192,543 shares and votes, equal to 3.14% of the total number of shares and votes in the Company calculated on the basis of the new share capital following completion of the Private Placement. Upon re-delivery of the lent shares, the consolidated shareholding will be further increased to 746,870 shares, equal to 12.19% of the total number of shares and votes in the company calculated on the basis of the new share capital following completion of the Private Placement, thereby crossing above the 5% and 10% reporting threshold pursuant to the NSTA.
The temporary share loans will be settled by re-delivery from the Managers of new shares in the Company to the share lenders following registration of the share capital increase pertaining to the Private Placement with the Norwegian Register of Business Enterprises.
Hadean Capital I AS, HVentures Capital I AB and Hadean Growth Fund I AS are persons closely associated with Ingrid Teigland Akay, member of the Board of Directors of the Company and Managing Partner of Hadean Ventures. See the attached PDMR forms for further information.
This information is subject to the disclosure requirements in article 19 of Regulation (EU) No 596/2014 (the EU Market Abuse Regulation) and section 4-2 of the NSTA.
For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com